2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Mucositis
4
Hematologic Neoplasms
3
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Thrombocytopenia
1
Sarcoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neutropenia
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphopenia
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Graft vs Host Disease
1
Cytopenia
1
Chondrosarcoma
1
Bone Neoplasms
1
Anemia
1
Interventions
Imatinib Mesylate
142
nilotinib
94
Cyclophosphamide
91
fludarabine phosphate
75
fludarabine
67
Dasatinib
63
Mycophenolic Acid
60
Whole-Body Irradiation
59
Tacrolimus
47
Busulfan
45
Cyclosporine
36
Peripheral Blood Stem Cell Transplantation
35
Cytarabine
35
Melphalan
30
bosutinib
27
ponatinib
26
Granulocyte Colony-Stimulating Factor
26
thymoglobulin
25
Thiotepa
25
Methotrexate
25
Filgrastim
25
asciminib
24
Antilymphocyte Serum
24
Stem Cell Transplantation
22
Sirolimus
17
Interferon-alpha
16
sargramostim
15
Cord Blood Stem Cell Transplantation
14
Clofarabine
13
Bone Marrow Transplantation
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
angiotensin I (1-7)
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled